Christos Rossios, Tufail Bashir, Marcus Achison, Simon Adamson, Asangaedem Akpan, Terry Aspray, Alison Avenell, Margaret M Band, Louise A Burton, Vera Cvoro, Peter T Donnan, Gordon W Duncan, Jacob George, Adam L Gordon, Celia L Gregson, Adrian Hapca, Cheryl Hume, Thomas A Jackson, Simon Kerr, Alixe Kilgour, Tahir Masud, Andrew McKenzie, Emma McKenzie, Harnish Patel, Kristina Pilvinyte, Helen C Roberts, Avan A Sayer, Karen T Smith, Roy L Soiza, Claire J Steves, Allan D Struthers, Divya Tiwari, Julie Whitney, Miles D Witham, Paul R Kemp
BACKGROUND: Angiotensin II (AII), has been suggested to promote muscle loss. Reducing AII synthesis, by inhibiting angiotensin converting enzyme (ACE) activity has been proposed as a method to inhibit muscle loss. The LACE clinical trial was designed to determine whether ACE inhibition would reduce further muscle loss in individuals with sarcopenia but suffered from low recruitment and returned a negative result. Polymorphic variation in the ACE promoter (I/D alleles) has been associated with differences in ACE activity and muscle physiology in a range of clinical conditions...
2023: PloS One